Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)

The systemic capillary leak syndrome (SCLS) is a rare disorder characterized by transient episodes of hypotensive shock and anasarca thought to arise from reversible microvascular barrier dysfunction. Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS suggests a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Ročník 119; číslo 18; s. 4321
Hlavní autoři: Xie, Zhihui, Ghosh, Chandra C, Patel, Roshni, Iwaki, Shoko, Gaskins, Donna, Nelson, Celeste, Jones, Nina, Greipp, Philip R, Parikh, Samir M, Druey, Kirk M
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 03.05.2012
Témata:
ISSN:1528-0020, 1528-0020
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract The systemic capillary leak syndrome (SCLS) is a rare disorder characterized by transient episodes of hypotensive shock and anasarca thought to arise from reversible microvascular barrier dysfunction. Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS suggests a pathogenic contribution of endogenous immunoglobulins, the mechanisms of vascular hyperpermeability remain obscure. Herein, we report clinical and molecular findings on 23 patients, the largest SCLS case series to date. Application of episodic SCLS sera, but neither the purified immunoglobulin fraction nor sera obtained from patients during remission, to human microvascular endothelial cells caused vascular endothelial cadherin internalization, disruption of interendothelial junctions, actin stress fiber formation, and increased permeability in complementary functional assays without inducing endothelial apoptosis. Intravenous immunoglobulin, one promising therapy for SCLS, mitigated the permeability effects of episodic sera. Consistent with the presence of endogenous, nonimmunoglobulin, circulating permeability factor(s) constrained to SCLS episodes, we found that vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2), were elevated in episodic SCLS sera but not in remission sera. Ab-based inhibition of Ang2 counteracted permeability induced by episodic SCLS sera. Comparable experiments with anti-VEGF Ab (bevacizumab) yielded less interpretable results, probably because of endothelial toxicity of VEGF withdrawal. Our results support a model of SCLS pathogenesis in which nonimmunoglobulin humoral factors such as VEGF and Ang2 contribute to transient endothelial contraction, suggesting a molecular mechanism for this highly lethal disorder.
AbstractList The systemic capillary leak syndrome (SCLS) is a rare disorder characterized by transient episodes of hypotensive shock and anasarca thought to arise from reversible microvascular barrier dysfunction. Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS suggests a pathogenic contribution of endogenous immunoglobulins, the mechanisms of vascular hyperpermeability remain obscure. Herein, we report clinical and molecular findings on 23 patients, the largest SCLS case series to date. Application of episodic SCLS sera, but neither the purified immunoglobulin fraction nor sera obtained from patients during remission, to human microvascular endothelial cells caused vascular endothelial cadherin internalization, disruption of interendothelial junctions, actin stress fiber formation, and increased permeability in complementary functional assays without inducing endothelial apoptosis. Intravenous immunoglobulin, one promising therapy for SCLS, mitigated the permeability effects of episodic sera. Consistent with the presence of endogenous, nonimmunoglobulin, circulating permeability factor(s) constrained to SCLS episodes, we found that vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2), were elevated in episodic SCLS sera but not in remission sera. Ab-based inhibition of Ang2 counteracted permeability induced by episodic SCLS sera. Comparable experiments with anti-VEGF Ab (bevacizumab) yielded less interpretable results, probably because of endothelial toxicity of VEGF withdrawal. Our results support a model of SCLS pathogenesis in which nonimmunoglobulin humoral factors such as VEGF and Ang2 contribute to transient endothelial contraction, suggesting a molecular mechanism for this highly lethal disorder.
The systemic capillary leak syndrome (SCLS) is a rare disorder characterized by transient episodes of hypotensive shock and anasarca thought to arise from reversible microvascular barrier dysfunction. Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS suggests a pathogenic contribution of endogenous immunoglobulins, the mechanisms of vascular hyperpermeability remain obscure. Herein, we report clinical and molecular findings on 23 patients, the largest SCLS case series to date. Application of episodic SCLS sera, but neither the purified immunoglobulin fraction nor sera obtained from patients during remission, to human microvascular endothelial cells caused vascular endothelial cadherin internalization, disruption of interendothelial junctions, actin stress fiber formation, and increased permeability in complementary functional assays without inducing endothelial apoptosis. Intravenous immunoglobulin, one promising therapy for SCLS, mitigated the permeability effects of episodic sera. Consistent with the presence of endogenous, nonimmunoglobulin, circulating permeability factor(s) constrained to SCLS episodes, we found that vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2), were elevated in episodic SCLS sera but not in remission sera. Ab-based inhibition of Ang2 counteracted permeability induced by episodic SCLS sera. Comparable experiments with anti-VEGF Ab (bevacizumab) yielded less interpretable results, probably because of endothelial toxicity of VEGF withdrawal. Our results support a model of SCLS pathogenesis in which nonimmunoglobulin humoral factors such as VEGF and Ang2 contribute to transient endothelial contraction, suggesting a molecular mechanism for this highly lethal disorder.The systemic capillary leak syndrome (SCLS) is a rare disorder characterized by transient episodes of hypotensive shock and anasarca thought to arise from reversible microvascular barrier dysfunction. Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS suggests a pathogenic contribution of endogenous immunoglobulins, the mechanisms of vascular hyperpermeability remain obscure. Herein, we report clinical and molecular findings on 23 patients, the largest SCLS case series to date. Application of episodic SCLS sera, but neither the purified immunoglobulin fraction nor sera obtained from patients during remission, to human microvascular endothelial cells caused vascular endothelial cadherin internalization, disruption of interendothelial junctions, actin stress fiber formation, and increased permeability in complementary functional assays without inducing endothelial apoptosis. Intravenous immunoglobulin, one promising therapy for SCLS, mitigated the permeability effects of episodic sera. Consistent with the presence of endogenous, nonimmunoglobulin, circulating permeability factor(s) constrained to SCLS episodes, we found that vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2), were elevated in episodic SCLS sera but not in remission sera. Ab-based inhibition of Ang2 counteracted permeability induced by episodic SCLS sera. Comparable experiments with anti-VEGF Ab (bevacizumab) yielded less interpretable results, probably because of endothelial toxicity of VEGF withdrawal. Our results support a model of SCLS pathogenesis in which nonimmunoglobulin humoral factors such as VEGF and Ang2 contribute to transient endothelial contraction, suggesting a molecular mechanism for this highly lethal disorder.
Author Jones, Nina
Nelson, Celeste
Greipp, Philip R
Druey, Kirk M
Iwaki, Shoko
Ghosh, Chandra C
Gaskins, Donna
Patel, Roshni
Parikh, Samir M
Xie, Zhihui
Author_xml – sequence: 1
  givenname: Zhihui
  surname: Xie
  fullname: Xie, Zhihui
  organization: Molecular Signal Transduction Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
– sequence: 2
  givenname: Chandra C
  surname: Ghosh
  fullname: Ghosh, Chandra C
– sequence: 3
  givenname: Roshni
  surname: Patel
  fullname: Patel, Roshni
– sequence: 4
  givenname: Shoko
  surname: Iwaki
  fullname: Iwaki, Shoko
– sequence: 5
  givenname: Donna
  surname: Gaskins
  fullname: Gaskins, Donna
– sequence: 6
  givenname: Celeste
  surname: Nelson
  fullname: Nelson, Celeste
– sequence: 7
  givenname: Nina
  surname: Jones
  fullname: Jones, Nina
– sequence: 8
  givenname: Philip R
  surname: Greipp
  fullname: Greipp, Philip R
– sequence: 9
  givenname: Samir M
  surname: Parikh
  fullname: Parikh, Samir M
– sequence: 10
  givenname: Kirk M
  surname: Druey
  fullname: Druey, Kirk M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22411873$$D View this record in MEDLINE/PubMed
BookMark eNpNkElLBDEQhYOMOIv-A5Ecx0Nrll6PMrjBgJfB65BOKkycLG2n-9An_7oRRxAKqnh8vHq8JZr54AGha0ruKK3ZfWtDUBkjlGakznhV1LQ8QwtasDojhJHZv3uOljF-EEJzzooLNGcsTx4VX6CvdxHlaEWPwaswHMAaYfFh6qBP40C0xpphwsarUULEicDSGm9kwuLkuiG4iIPGm-RxjMFjZSKICHj9g8YpDuCMxFJ0xiZkwhbEMele9cHB7SU618JGuDrtFdo9Pe42L9n27fl187DNZN7wIeNQVBVwVVKldUFzrXkJZVNSoHkl2kKWkJeaNg2vNGuqPBFSQaFbXUvJWrZC61_brg-fI8Rh70yUkBJ5CGPc01QjbdIrntCbEzq2DtS-641Lufd_nbFv41p04Q
CitedBy_id crossref_primary_10_1186_s13023_019_1263_6
crossref_primary_10_1016_j_revmed_2014_11_005
crossref_primary_10_1007_s10238_021_00693_0
crossref_primary_10_1371_journal_pone_0133266
crossref_primary_10_1136_bcr_2017_221068
crossref_primary_10_1371_journal_pone_0251775
crossref_primary_10_1097_SHK_0000000000001254
crossref_primary_10_1093_ehjcr_ytaa013
crossref_primary_10_1111_all_12862
crossref_primary_10_3389_fimmu_2021_641427
crossref_primary_10_1111_ped_14345
crossref_primary_10_3389_fmed_2018_00111
crossref_primary_10_1002_ccr3_3811
crossref_primary_10_1111_jcmm_14381
crossref_primary_10_1007_s11739_019_02113_4
crossref_primary_10_1186_1471_2431_14_137
crossref_primary_10_1002_ccr3_280
crossref_primary_10_1186_s12967_022_03587_1
crossref_primary_10_1097_SHK_0b013e31829f91fc
crossref_primary_10_1053_j_jvca_2015_02_016
crossref_primary_10_1016_j_ccc_2019_12_003
crossref_primary_10_1007_s12185_020_03011_8
crossref_primary_10_1093_ehjcr_ytac262
crossref_primary_10_1007_s40620_025_02250_4
crossref_primary_10_1016_j_jcrpr_2016_09_004
crossref_primary_10_3390_biomedicines13010008
crossref_primary_10_3389_fimmu_2020_535147
crossref_primary_10_1111_imj_12271
crossref_primary_10_1016_j_annder_2020_04_021
crossref_primary_10_1016_j_critrevonc_2016_09_004
crossref_primary_10_1136_bcr_2019_232500
crossref_primary_10_1155_2021_8098942
crossref_primary_10_1007_s00108_018_0409_2
crossref_primary_10_1213_XAA_0000000000000808
crossref_primary_10_1002_JLB_5A0817_324R
crossref_primary_10_1097_INF_0000000000000029
crossref_primary_10_1161_CIRCRESAHA_122_322332
crossref_primary_10_36290_vnl_2019_078
crossref_primary_10_1111_bjh_15644
crossref_primary_10_1016_j_kint_2019_03_001
crossref_primary_10_1016_j_biopha_2024_116147
crossref_primary_10_1111_joim_13641
crossref_primary_10_1007_s00018_017_2624_8
crossref_primary_10_1016_j_jaci_2016_10_042
crossref_primary_10_1089_ct_2020_32_450_453
crossref_primary_10_1016_j_amjmed_2017_05_023
crossref_primary_10_1159_000533957
crossref_primary_10_1007_s40487_024_00263_w
crossref_primary_10_1186_s40001_024_01738_2
crossref_primary_10_1016_j_yexcr_2013_03_011
crossref_primary_10_1096_fj_201802052RRR
crossref_primary_10_1016_j_amsu_2021_103013
crossref_primary_10_1016_j_ajem_2014_11_057
crossref_primary_10_3390_jcm10225415
crossref_primary_10_1016_j_jaip_2017_07_021
crossref_primary_10_4081_btvb_2025_152
crossref_primary_10_1016_j_kint_2016_11_029
crossref_primary_10_3389_fmed_2019_00089
crossref_primary_10_1186_s40635_023_00582_8
crossref_primary_10_1164_rccm_201301_0136LE
crossref_primary_10_1172_JCI180795
crossref_primary_10_1007_s11739_025_03890_x
crossref_primary_10_1172_JCI169137
crossref_primary_10_1186_s12879_025_10699_8
crossref_primary_10_3390_jcm8020143
crossref_primary_10_1161_ATVBAHA_124_321522
crossref_primary_10_1080_17843286_2020_1792685
crossref_primary_10_1136_bcr_2022_253045
crossref_primary_10_1136_bcr_2018_226108
crossref_primary_10_3389_fimmu_2022_1050994
crossref_primary_10_1177_23993693231176883
crossref_primary_10_1016_j_hrtlng_2018_04_008
crossref_primary_10_1038_s41409_022_01874_5
crossref_primary_10_3390_diagnostics14171924
crossref_primary_10_1186_s12887_019_1401_2
crossref_primary_10_3390_jcm14061871
crossref_primary_10_1038_s41572_024_00571_5
crossref_primary_10_3389_fgene_2023_1282711
crossref_primary_10_2217_imt_2020_0335
crossref_primary_10_1111_jdv_13847
crossref_primary_10_1111_tbj_12866
crossref_primary_10_1111_petr_12831
crossref_primary_10_1097_AAP_0000000000000302
crossref_primary_10_1111_ddg_15336
crossref_primary_10_1038_s41598_020_59269_9
crossref_primary_10_1016_j_medcli_2020_05_056
crossref_primary_10_1097_MD_0000000000000591
crossref_primary_10_1016_j_anndiagpath_2022_152028
crossref_primary_10_7759_cureus_77261
crossref_primary_10_3390_jcm11030623
crossref_primary_10_7759_cureus_38335
crossref_primary_10_1038_nrd_2016_278
crossref_primary_10_1186_s12968_015_0181_6
crossref_primary_10_1513_AnnalsATS_202411_1214CC
crossref_primary_10_1007_s10456_021_09769_7
crossref_primary_10_1073_pnas_1519467113
crossref_primary_10_1007_s10456_016_9537_2
crossref_primary_10_1213_XAA_0000000000001537
crossref_primary_10_7759_cureus_14370
crossref_primary_10_1080_14779072_2018_1456920
crossref_primary_10_1155_2015_958283
crossref_primary_10_3201_eid2710_211155
crossref_primary_10_1007_s10875_019_00722_4
crossref_primary_10_1016_j_semarthrit_2016_08_001
crossref_primary_10_1097_MD_0000000000002648
crossref_primary_10_1515_bj_2015_0019
crossref_primary_10_1038_s42003_019_0647_4
crossref_primary_10_1186_s41100_021_00371_7
crossref_primary_10_1590_abd1806_4841_20175994
crossref_primary_10_1186_s13054_023_04496_5
crossref_primary_10_1016_j_revmed_2021_03_325
crossref_primary_10_1007_s11897_023_00618_w
crossref_primary_10_1161_CIRCHEARTFAILURE_119_006097
crossref_primary_10_1016_j_revmed_2021_05_012
crossref_primary_10_1016_j_jaci_2018_09_001
crossref_primary_10_1016_j_medcle_2021_07_004
crossref_primary_10_3390_biomedicines10102379
crossref_primary_10_1089_cmb_2019_0222
crossref_primary_10_1161_CIRCRESAHA_116_306534
crossref_primary_10_3390_biomedicines10061221
crossref_primary_10_1111_bjh_20193
crossref_primary_10_1038_nm_4057
crossref_primary_10_1177_08850666231193955
crossref_primary_10_1097_MD_0000000000010716
crossref_primary_10_1016_j_accpm_2015_05_003
crossref_primary_10_3389_fimmu_2024_1403376
crossref_primary_10_12998_wjcc_v9_i33_10273
crossref_primary_10_3389_fimmu_2022_1045002
crossref_primary_10_1111_cea_13506
crossref_primary_10_1111_ddg_15336_g
crossref_primary_10_1016_j_neuroscience_2019_07_044
crossref_primary_10_1016_S2665_9913_21_00348_9
crossref_primary_10_1586_1744666X_2014_882771
crossref_primary_10_3389_fphar_2023_1242970
crossref_primary_10_1186_s13256_016_0894_7
crossref_primary_10_1002_ajum_12320
crossref_primary_10_1016_j_anai_2017_02_013
crossref_primary_10_1084_jem_20162143
crossref_primary_10_3390_jcm7110418
crossref_primary_10_1164_rccm_201310_1746LE
crossref_primary_10_1007_s12254_021_00789_z
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1182/blood-2011-08-375816
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
ExternalDocumentID 22411873
Genre Journal Article
Research Support, N.I.H., Intramural
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: Intramural NIH HHS
– fundername: NHLBI NIH HHS
  grantid: R01HL093234-01S1
– fundername: NIAID NIH HHS
  grantid: AI001083
– fundername: NIDDK NIH HHS
  grantid: K08DK06916
– fundername: NHLBI NIH HHS
  grantid: R01HL093234
– fundername: NHLBI NIH HHS
  grantid: R01 HL093234
GroupedDBID ---
-~X
.55
0R~
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6J9
AAEDW
AALRI
AAXUO
ABOCM
ACGFO
ADBBV
ADVLN
AENEX
AFOSN
AITUG
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BTFSW
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
EX3
F5P
FDB
FRP
GS5
GX1
H13
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
NPM
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
7X8
ACVFH
ADCNI
AEUPX
AFPUW
AIGII
AKBMS
AKYEP
EFKBS
ID FETCH-LOGICAL-c493t-3e577e3d61dff514ff36e6961e147ab5c6e46f19937f297414fcde5fbf8cc2b2
IEDL.DBID 7X8
ISICitedReferencesCount 156
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000305284600030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1528-0020
IngestDate Sun Sep 28 00:26:01 EDT 2025
Wed Feb 19 02:30:28 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 18
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c493t-3e577e3d61dff514ff36e6961e147ab5c6e46f19937f297414fcde5fbf8cc2b2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://dx.doi.org/10.1182/blood-2011-08-375816
PMID 22411873
PQID 1011194933
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1011194933
pubmed_primary_22411873
PublicationCentury 2000
PublicationDate 2012-05-03
PublicationDateYYYYMMDD 2012-05-03
PublicationDate_xml – month: 05
  year: 2012
  text: 2012-05-03
  day: 03
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Blood
PublicationTitleAlternate Blood
PublicationYear 2012
SSID ssj0014325
Score 2.4677198
Snippet The systemic capillary leak syndrome (SCLS) is a rare disorder characterized by transient episodes of hypotensive shock and anasarca thought to arise from...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 4321
SubjectTerms Acute Disease
Adherens Junctions - drug effects
Adherens Junctions - ultrastructure
Adult
Aged
Angiopoietin-2 - antagonists & inhibitors
Angiopoietin-2 - blood
Antibodies, Monoclonal, Humanized - pharmacology
Apoptosis - drug effects
Bevacizumab
Capillary Leak Syndrome - blood
Capillary Leak Syndrome - etiology
Capillary Leak Syndrome - physiopathology
Capillary Permeability
Cells, Cultured - drug effects
Chronic Disease
Convalescence
Cytoskeleton - ultrastructure
Endothelial Cells - drug effects
Endothelium, Vascular - physiopathology
Female
Humans
Immunoglobulins, Intravenous - therapeutic use
Male
Middle Aged
Paraproteinemias - blood
Paraproteinemias - complications
Recombinant Proteins - pharmacology
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Vascular Endothelial Growth Factor A - blood
Vascular Endothelial Growth Factor A - genetics
Vascular Endothelial Growth Factor A - pharmacology
Title Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)
URI https://www.ncbi.nlm.nih.gov/pubmed/22411873
https://www.proquest.com/docview/1011194933
Volume 119
WOSCitedRecordID wos000305284600030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB5868VHfb8YQUQPQfLaJCfRYvFgiweR3kKyDyzapDYq9ORfd3azsSdBEELIYfPcye43M9_OB3DKaBoXIiDvJMlCJwhyTQKIMscNZRhkrqdiw3Z_uo96vbjfTx5swK2ytMpmTDQDtSi5jpHT301_ZRKQ_301enO0apTOrloJjVmY9wnKaEpX1J9mEQLfiK7SFBU7GhfZpXMEqS9rWvhPgJBQs8t-B5lmsums_fcx12HVwky8ru1iA2Zk0YLN64Jc7OEEz9AQP01EvQWLN83RcruRf2vBUtdm3Tfh68nSVVEWQq_YeiWjxWfyYMe0DWVd6nuC5N6ToVRILbBZcYnVZDiim1ZYKjRkIAL4aNNCeK6b1sWkBxx5NtIaSOMJvsrsBZtiChdb8Ni5fWzfOVa4weH05u-OL8Mokr5grlCKEJlSPpMsYa50gyjLQ85kwJSmDkbKI4eGWnAhQ5WrmHMv97ZhrigLuQsotCZaEiuhpQNlKAivCEYTqCLcxwnr7MFJ0w0pfR-d7MgKWX5U6bQj9mCn7st0VBfwSDVsoQv6-384-wBWyEo8w3H0D2Fe0aggj2CBf74PqvGxMTja9x66355G4PM
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vascular+endothelial+hyperpermeability+induces+the+clinical+symptoms+of+Clarkson+disease+%28the+systemic+capillary+leak+syndrome%29&rft.jtitle=Blood&rft.au=Xie%2C+Zhihui&rft.au=Ghosh%2C+Chandra+C&rft.au=Patel%2C+Roshni&rft.au=Iwaki%2C+Shoko&rft.date=2012-05-03&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=119&rft.issue=18&rft.spage=4321&rft_id=info:doi/10.1182%2Fblood-2011-08-375816&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon